Hormone Therapy Linked to Increased Cardiovascular Risk in Women with type 2 diabetes
Vienna, Austria - New data presented at the annual conference of the European Association for the Study of Diabetes (EASD) suggests hormone therapy may elevate cardiovascular risk in postmenopausal women with type 2 diabetes. The research, unveiled in Vienna as Abstract 1181, indicates that transdermal hormone administration – via a patch – could potentially be safer than oral hormone preparations.
For years, hormone replacement therapy (HRT) faced scrutiny following the Women’s Health initiative, which linked it to increased cardiovascular events and breast disease in older women.However, estrogen-gestagen preparations are now being more frequently prescribed to manage menopausal symptoms, typically for a limited duration. This new analysis adds a layer of complexity to that evolving understanding, notably for women with pre-existing diabetes.
The study, a database analysis, highlights the need for careful consideration of hormone therapy options in diabetic postmenopausal women, suggesting a potential benefit to utilizing transdermal delivery methods to minimize cardiovascular risk.Further research is needed to confirm these findings and establish clear guidelines for hormone therapy use in this specific patient population.
